The Clinical Effect of Factor XIII on Drug-induced Hemorrhagic Cystitis

Bibliographic Information

Other Title
  • 薬剤性出血性膀胱炎に対する血液凝固第XIII因子製剤の有効性についての検討

Abstract

The therapeutic effects of Factor XIII (F XIII) concentrate against drug-induced hemorrhagic cystitis (HC) was investigated. HC ocurred in 4 children with malignant disease during anti-cancer chemotherapy. Two (CML and T-ALL) of 4 patients developed HC after the administration of high dose cyclophosphamide as conditioning for allo bone marrow transplantation or peripheral blood stem cell autografts, and the otehr 2 patients (rhabdomyosarcoma, Wilm's tumor) developed HC after the administration of ifosfamide for relapse. When F XIII concentrate at a dose of 20 to 230 U/kg was administrated immediately after the onset of HC, the symptomes, i.e., bladder irritability and macrohematuria disappeared within a few days. The F XIII serum levels of those patients were low (27∼57%), and the levels increased (63∼230%) after administration of F XIII concentrate. The two patients with relapsed solid tumor showed no symptoms of HC during subsequent ifosfamide treatment when F XIII concentrate was administrated to maintain a normal F XIII range. These results suggest that the administration of F XIII concentrate may be useful for the prophylaxis and treatment of drug-induced HC in patients with a low F XIII level.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 35 (3), 279-285, 1994

    The Japanese Society of Hematology

Details 詳細情報について

  • CRID
    1390282680004261632
  • NII Article ID
    130004500056
  • DOI
    10.11406/rinketsu.35.279
  • COI
    1:STN:280:DyaK2c3htVOhsg%3D%3D
  • ISSN
    18820824
    04851439
  • PubMed
    8158849
  • Text Lang
    ja
  • Data Source
    • JaLC
    • PubMed
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top